Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA.

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Stock price predictions for 2025 are increasingly "meta." No, not the Facebook parent, but rather the idea that investments are increasingly self-referential rather than reliant on outside ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

Editas Medicine, Inc.’s EDIT share price has surged by 16.48%, which has investors questioning if this is right time to sell.

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

But these aren't the only areas that offer the potential for explosive revenue growth and stock performance ... for the ...

The expansion will significantly increase Core Scientific’s AI and cloud computing capacity and increase total projected ...